Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ZS Pharma readies NDA as competitor Relypsa's filing nears

This article was originally published in Scrip

Executive Summary

ZS Pharma will seek US and EU approvals for its hyperkalemia drug ZS-9 (sodium zirconium cyclosilicate) in 2015 based on two sets of positive Phase III results, but Relypsa is ahead of the game with plans to submit a new drug application (NDA) to the US FDA this year for its competing therapy patiromer.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts